CYTK Profile
Cytokinetics, Incorporated, headquartered in South San Francisco, California, is a leading biopharmaceutical firm specializing in the research, development, and potential commercialization of muscle activators and inhibitors aimed at addressing debilitating diseases. Founded in 1997, the company focuses on advancing small molecule drug candidates designed to modulate muscle function and contractility.
At the forefront of Cytokinetics' pipeline is omecamtiv mecarbil, a pioneering cardiac myosin activator currently undergoing Phase III clinical trials for patients grappling with heart failure. Additionally, reldesemtiv, a skeletal muscle troponin activator, is also in Phase III clinical trials, targeting conditions such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy.
Further expanding its therapeutic portfolio, Cytokinetics is advancing CK-136, a novel cardiac troponin activator currently in Phase I clinical trials. The company's innovative efforts also encompass aficamten, a cardiac myosin inhibitor in Phase III clinical trials for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, as well as CK-3772271, a small molecule cardiac myosin inhibitor currently undergoing Phase I clinical trials.
In pursuit of its mission to pioneer breakthrough treatments, Cytokinetics has strategically aligned itself with Astellas Pharma Inc., enhancing its capabilities and resources in the biopharmaceutical arena. With a steadfast commitment to innovation and therapeutic advancement, Cytokinetics continues to position itself as a key player in the development of treatments that address critical unmet medical needs globally.
|
